touchCONGRESS Should we use third-generation TKIs up front in EGFR+ NSCLC?

In this interview James Yang answers the following questions:

• Which data on 3rd-generation EGFR TKIs in NSCLC stood out for you at ESMO Asia 2019 and why?
• This year’s ESMO Asia congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC, particularly following progression. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• What do you think is the potential role for combining EGFR TKIs with other therapies in the future?
• What is your current strategy for monitoring patients with EGFR-mutated NSCLC during therapy? Given the new data presented at ESMO Asia 2019, how do you think this may change in the future?

Prof. James Yang is currently the director and distinguished professor of the Graduate Institute of Oncology at National Taiwan University. He is also the director of the Department of Oncology at the National Taiwan University Hospital, Taiwan. He has served on the editorial board of Annals of Oncology and Lung Cancer and is the current associate editor of the Journal of Thoracic Oncology and Nature Scientific Report.

Prof. Yang’s research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Prof. Yang is a leader in lung cancer clinical studies, especially in the new drug development for lung cancer treatment. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS).

Prof. Yang discloses: Advisory Board & Speech with AstraZeneca, BMS, Boehringer Ingelheim, Chugai Pharmaceutical, Eli Lilly, Merck Serono, MSD, Novartis, Ono Pharmaceutical, Pfizer, Roche/Genentech and Takeda Oncology. Advisory Board with Bayer, Blueprint Medical, Celgene, Daiichi-Sankyo, G1 Therapeutics, Hansoh Pharmaceutical, Merrimack and Yuhan Pharmaceutical.  Principal Investigator with AstraZeneca, Boehringer Ingelheim, Eli Lilly

In this interview Keunchil Park answers the following questions:

• Which data on 3rd-generation EGFR TKIs in NSCLC stood out for you at ESMO Asia 2019 and why?
• This year’s ESMO Asia congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC, particularly following progression. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• What do you think is the potential role for combining EGFR TKIs with other therapies in the future?
• What is your current strategy for monitoring patients with EGFR-mutated NSCLC during therapy? Given the new data presented at ESMO Asia 2019, how do you think this may change in the future?

Prof. Park is currently the Professor, Division of Hematology-Oncology at Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

He is on the Editorial Board of the Asia-Pacific Journal of Clinical Oncology, and Associate Editor of the Journal of Thoracic Oncology and Therapeutic Advances in Medical Oncology.

Prof Park’s professional interests lie in experimental and translational research in lung, head and neck, and esophageal cancers; early clinical trials; and the development of experimental therapeutics. The institute he leads focuses heavily on data management and clinical and preclinical trials, particularly exploring precision medicine and genome analysis.

Prof. Park discloses: Consulting or Advisory Role with Abbvie, AMGEN, Astellas Pharma, AstraZeneca, BluePrint, BMS, Boehringer Ingelheim, Clovis Oncology, Daiichi Sankyo, Eli Lilly, GSK, Hanmi, Incyte, Kyowa Hakko Kirin, LOXO, Merck KGaA, MSD, Novartis, Ono Pharmaceutical and Roche.  Speakers’ Bureau with AstraZeneca and Boehringer Ingelheim.  Research Funding with AstraZeneca and MSD

In this interview Suresh Ramalingam answers the following questions:s@

• What does the real-world evidence regarding third-generation EGFR TKIs presented at ESMO 2019 tell us about their efficacy and safety compared with the results reported in clinical trials?
• This year’s ESMO congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• How will the data presented at ESMO 2019 inform your treatment decisions for patients who progress on third-generation agents?
• How can clinicians best employ biomarker testing in their practice, particularly for resistance to first- and second-generation EGFR TKIs?
• Which data on EGFR+ NSCLC stood out for you at ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Ramalingam is Professor of Hematology and Medical Oncology and Director of the Division of Medical Oncology at the Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA, USA. Prof. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He also serves on the Editorial Board of leading cancer journals such as the Journal of Clinical Oncology, Cancer, Annals of Oncology and Clinical Lung Cancer.

Prof. Ramalingam’s research interests include development of novel anti-cancer agents and evaluation of methods to individualize therapies for patients. Prof. Ramalingam has conducted several clinical trials with molecularly targeted agents in the treatment of small cell and non-small cell lung cancer.

Prof. Suresh Ramalingam discloses: Consultancy role with AstraZeneca, AbbVie, Amgen, Bristol Myers Squibb, Genentech, Merck, and Takeda. Research funding from Advaxis, Amgen, AstraZeneca, Bristol Myers Squibb, Merck and Tesaro.

In this interview Frank Griesinger answers the following questions:

• What does the real-world evidence regarding third-generation EGFR TKIs presented at ESMO 2019 tell us about their efficacy and safety compared with the results reported in clinical trials?
• This year’s ESMO congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• How will the data presented at ESMO 2019 inform your treatment decisions for patients who progress on third-generation agents?
• How can clinicians best employ biomarker testing in their practice, particularly for resistance to first- and second-generation EGFR TKIs?
• Which data on EGFR+ NSCLC stood out for you at ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Griesinger is a Director of the Department of Haematology and Oncology at the Pius-Hospital, Oldenburg, lecturer at the University of Göttingen, and holds a Professorship in Oncology at the University of Oldenburg, Germany. He has been active in Phase II and III trials in lung cancer and has specialized in studies in the neoadjuvant setting. Prof. Griesinger is a member of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the International Association for the Study of Lung Cancer (IASLC) and the steering committee of the Thoracic Oncology Group of the Arbeitsgemeinschaft Internistische Onkologie (AIO) in Germany.

Prof. Griesinger has further researched interests in the treatment of molecular subgroups of lung cancer. He is currently very involved in the introduction of molecular stratified treatments in the treatment of lung cancer in Germany and is the first author of the guidelines of the German Society of Haematology and Oncology for the treatment of Non-Small-Cell-Lung Cancer.

Prof. Frank Griesinger Disclosures: Abbvie, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, Elli Lilly, Medac, Merck, Merck Sharp & Dohme, Novartis, Pfizer, Roche and Takeda.

In this interview Liyan Jiang answers the following questions:

• What does the real-world evidence regarding third-generation EGFR TKIs presented at ESMO 2019 tell us about their efficacy and safety compared with the results reported in clinical trials?
• This year’s ESMO congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• How will the data presented at ESMO 2019 inform your treatment decisions for patients who progress on third-generation agents?
• How can clinicians best employ biomarker testing in their practice, particularly for resistance to first- and second-generation EGFR TKIs?
• Which data on EGFR+ NSCLC stood out for you at ESMO 2019 and why? What are their implications for clinical practice in your region?

Prof. Jiang is the Director of the Office for the National Agency for Clinical Trials of Drugs at the Shanghai Chest Hospital, Deputy Director of the Clinical Research Office of Lung Cancer in Shanghai Chest Tumour Institute and Deputy Director of the Department of Pulmonary Medicine of the Shanghai Chest Hospital as well as the Chair of the Academic Committee of Thoracic Oncology Society of CMEA (China Medicine Education Association). She is also a member of the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC), the IASLC Staging and Prognostic Factors Committee (SPFC) and the Chinese Society of Clinical Oncology (CSCO).

She has carried out several bureau- or higher-level research projects, including one international cooperation project, four projects supported by the Shanghai Science and Technology Commission, one project supported by the Key Basic Projects of Shanghai Science and Technology Commission, and one project supported by the Youth Research Foundation of Shanghai Health Bureau. Prof. Jiang is interested in combining new resources for a translational medicine approach.

Prof. Liyan Jiang discloses: Advisory board and consulting fee from AstraZeneca. Consulting fee from BETTA, Bristol Myers Squib Roche, Merck Sharp & Dohme, Novartis and Pfizer.

In this interview Yasushi Goto answers the following questions:

• What does the real-world evidence regarding third-generation EGFR TKIs presented at ESMO 2019 tell us about their efficacy and safety compared with the results reported in clinical trials?
• This year’s ESMO congress has seen a lot of discussion regarding the optimal sequence for treatment in EGFR+ NSCLC. What are your thoughts on how best to sequence treatment to increase the personalization of care given to patients?
• How will the data presented at ESMO 2019 inform your treatment decisions for patients who progress on third-generation agents?
• How can clinicians best employ biomarker testing in their practice, particularly for resistance to first- and second-generation EGFR TKIs?
• Which data on EGFR+ NSCLC stood out for you at ESMO 2019 and why? What are their implications for clinical practice in your region?

Dr Goto is a Senior Consultant at Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan. He is a member of the American Society of Clinical Oncology (ASCO), European Society of Medical Oncology (ESMO), the Japanese Society of Internal Medicine, the Japan Lung Cancer Society, the Japanese Respiratory Society and the Japanese Cancer Association, as well as a Communication Committee member of the International Association for the Study of Lung Cancer and Chief of Secretariat for the Japanese Society of Medical Oncology.

Dr Goto’s research interests include translational medicine approaches for thoracic malignancies.

Dr Yasushi Goto Discloses: Consulting or advisory role for AstraZeneca, Boehringer Ingelheim, Chugai, Eli Lilly, Glaxo Smith Kline, Guardant Health, Novartis, Merck Sharp & Dohme, Pfizer and Taiho Pharmaceutical. Speaker’s bureau attendee for AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Chugai, Eli Lilly, Merck Sharp & Dohme, Novartis, Ono Pharmaceutical, Pfizer, Shionogi Pharma and Taiho Pharmaceutical. Research Funding from AbbVie, Bristol Myers Squibb, Chugai, Dai-ichi Sankyo, Eli Lilly, Kyorin, Novartis, Ono Pharmaceutical, Pfizer and Taiho Pharmaceutical.